

REMARKS

Status of the claims

Claims 2, 4-7, 12-15, and 19-31 are currently pending. Claims 2, 6, 7, 13, 14, 19, 20, 23-26, and 29-31 are allowed. Claims 4, 15, 21, and 27 stand rejected under 35 U.S.C. §112, first paragraph. Claims 5, 22, and 28 stand rejected under §112, second paragraph.

Clarification of the status of claim 12 is respectfully requested, as the Office action does not specifically state the same.

Claim 5 has been amended to correct an obvious typographical error. Support for this amendment may be found, for example, at the third full paragraph on page 6 of the subject specification.

35 U.S. C. §112, first paragraph rejection

Reconsideration is respectfully requested of the rejection of claims 4, 15, 21, and 27 under §112, first paragraph.

The Office asserts that claims 4, 21, and 27 fail to comply with the written description requirement. Specifically, the Office asserts that the specification does not describe the term "discrete solid particles [sic]." Applicants respectfully disagree. Claims 4, 21, and 27 refer to discrete solid **articles**, not particles. Support for discrete solid **articles** may be found, for example, at the third full paragraph on page 6 of the subject specification, which states:

The dose units comprising the composition can be in the form of discrete solid articles such as tablets, pills, hard or soft capsules, lozenges, sachets or pastilles

Thus, claims 4, 21, and 27 satisfy the written description requirement of §112, first paragraph.

Likewise, claim 15 satisfies the written description requirement of §112, first paragraph. Claim 15 requires a dose range of "about 10 mg to about 1000 mg." Support for this dose range may be found at the third full paragraph on page 8 of the subject specification.

35 U.S. C. §112, second paragraph rejection

Reconsideration is respectfully requested of the rejection of claims 5, 22, and 28 under §112, second paragraph as being indefinite.

Claim 5 has been amended to correct an obvious typographical error (by replacing "particles" with "articles"). Support for this amendment may be found, for example, at the third full paragraph on page 6 of the subject specification. Neither claim 22 nor claim 28 refer to solid

Application Serial No. 10/031,898 [Attorney Docket No. PC31214/1A]
Amendment dated September 26, 2006
Reply to Office action dated May 3, 2006

particles; rather, these claims refer to solid articles. Applicants submit that claims 5, as amended, and claims 22 and 28 satisfy the definiteness requirement of §112, second paragraph.

Conclusion

Applicants submit that the present invention is now in condition for allowance. Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Patricia K. Fitzsimmons".

Patricia K. Fitzsimmons
Registration No. 52,894

Pharmacia Corporation
Post Office Box 1027
St. Louis, MO 63006
Telephone: 314.274.1490
Facsimile: 314.274.9095